idebenone has been researched along with Cardiomyopathy, Hypertrophic in 6 studies
Cardiomyopathy, Hypertrophic: A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This paper reviews the history and pre-clinical development of idebenone and summarises the results of clinical studies, published from 1999 to 2008, on the use of idebenone in the treatment of patients with Friedreich ataxia (FRDA)." | 8.85 | Idebenone: an emerging therapy for Friedreich ataxia. ( Buyse, G; Meier, T, 2009) |
| "Severe hypertrophic cardiomyopathy in a 15 years old child with Friedreich ataxia was treated with idebenone on the basis of a preliminary study reported in the literature." | 7.72 | [Successful idebenone therapy of hypertrophic cardiomyopathy in Friedreich ataxia]. ( Kádár, K, 2003) |
| "The authors carried out a 1-year, randomized, placebo-controlled trial of idebenone in 29 patients with Friedreich ataxia." | 5.10 | Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. ( Di Donato, S; Fiorentini, C; Marano, L; Mariotti, C; Solari, A; Torta, D, 2003) |
| "This paper reviews the history and pre-clinical development of idebenone and summarises the results of clinical studies, published from 1999 to 2008, on the use of idebenone in the treatment of patients with Friedreich ataxia (FRDA)." | 4.85 | Idebenone: an emerging therapy for Friedreich ataxia. ( Buyse, G; Meier, T, 2009) |
| "Severe hypertrophic cardiomyopathy in a 15 years old child with Friedreich ataxia was treated with idebenone on the basis of a preliminary study reported in the literature." | 3.72 | [Successful idebenone therapy of hypertrophic cardiomyopathy in Friedreich ataxia]. ( Kádár, K, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meier, T | 2 |
| Buyse, G | 2 |
| Lagedrost, SJ | 1 |
| Sutton, MS | 1 |
| Cohen, MS | 1 |
| Satou, GM | 1 |
| Kaufman, BD | 1 |
| Perlman, SL | 1 |
| Rummey, C | 1 |
| Lynch, DR | 1 |
| Mariotti, C | 1 |
| Solari, A | 1 |
| Torta, D | 1 |
| Marano, L | 1 |
| Fiorentini, C | 1 |
| Di Donato, S | 1 |
| Mertens, L | 1 |
| Di Salvo, G | 1 |
| Matthijs, I | 1 |
| Weidemann, F | 1 |
| Eyskens, B | 1 |
| Goossens, W | 1 |
| Goemans, N | 1 |
| Sutherland, GR | 1 |
| Van Hove, JL | 1 |
| Kádár, K | 1 |
| Rustin, P | 1 |
| Rötig, A | 1 |
| Munnich, A | 1 |
| Sidi, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients[NCT00537680] | Phase 3 | 70 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | g/m2 (Mean) |
|---|---|
| Mid Dose Idebenone | -3.06 |
| High Dose Idebenone | -2.56 |
| Placebo | -1.26 |
To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | cm (Mean) |
|---|---|
| Mid Dose Idebenone | -0.032 |
| High Dose Idebenone | 0.007 |
| Placebo | 0.010 |
To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | cm (Mean) |
|---|---|
| Mid Dose Idebenone | -0.014 |
| High Dose Idebenone | 0.021 |
| Placebo | 0.063 |
To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | cm (Mean) |
|---|---|
| Mid Dose Idebenone | -0.018 |
| High Dose Idebenone | -0.004 |
| Placebo | -0.038 |
"To compare the efficacy of 6 months' treatment with 2 different doses of idebenone with that of placebo on Activities of Daily Living (ADL) assessed by the ADL scale of the Friedreich's Ataxia Rating Scale (FARS)~score 0 to 36, higher score indicates greater impairment" (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | ADL points (Mean) |
|---|---|
| Mid Dose Idebenone | 0.2 |
| High Dose Idebenone | 0.6 |
| Placebo | 1.0 |
"To compare the efficacy of 6 months' treatment with 2 different doses of idebenone with that of placebo on neurological function as assessed by the Friedreich's Ataxia Rating Scale (FARS)~FARS consists of a 25 manoeuvre exam along with 4 quantitative performance measures. The neurological exam covers bulbar function, upper limb coordination, lower limb coordination, peripheral nervous system function, deep tendon reflexes, stability and gait. The use of FARS has been recently validated as a sensitive scale for this population.~The FARS exam scores can be added to make a total score ranging from 0 to 159. A higher score indicates a greater level of disability.~Calculation details FARS score at week 24 minus FARS score baseline" (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | FARS score (Mean) |
|---|---|
| Mid Dose Idebenone | -1.6 |
| High Dose Idebenone | -1.2 |
| Placebo | 0.6 |
"To compare the efficacy of 3 months' treatment with 2 different doses of idebenone with that of placebo on neurological impairment as assessed by the International Cooperative Ataxia Rating Scale (ICARS)~International Cooperative Ataxia Rating Scale (ICARS):~ICARS consists of a one-hundred-point semi-quantitative scale based upon 19 simple testing manoeuvres compartmentalized into postural and stance disorders, limb ataxia, dysarthria and oculomotor disorders and has been previously used in this patient population with good inter-rater reliability.~Minimum score: 0, maximum score 100, higher score indicates greater impairment~Calculation details: ICARS score at week 12 minus ICARS score baseline" (NCT00537680)
Timeframe: baseline and 12 weeks
| Intervention | ICARS points (Mean) |
|---|---|
| Mid Dose Idebenone | -1.5 |
| High Dose Idebenone | -1.6 |
| Placebo | -3.0 |
"International Cooperative Ataxia Rating Scale (ICARS):~ICARS consists of a one-hundred-point semi-quantitative scale based upon 19 simple testing manoeuvres compartmentalized into postural and stance disorders, limb ataxia, dysarthria and oculomotor disorders and has been previously used in this patient population with good inter-rater reliability.~Minimum score: 0, maximum score 100, higher score indicates greater impairment~Calculation details: ICARS score at week 24 minus ICARS score baseline" (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | ICARS points (Mean) |
|---|---|
| Mid Dose Idebenone | -2.5 |
| High Dose Idebenone | -2.4 |
| Placebo | -1.3 |
To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | % change (Mean) |
|---|---|
| Mid Dose Idebenone | -4.5 |
| High Dose Idebenone | -4.9 |
| Placebo | -1.7 |
To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | % change (Mean) |
|---|---|
| Mid Dose Idebenone | -3.32 |
| High Dose Idebenone | 1.53 |
| Placebo | 2.65 |
To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 24 weeks
| Intervention | % change (Mean) |
|---|---|
| Mid Dose Idebenone | 1.3 |
| High Dose Idebenone | 2.6 |
| Placebo | 7.8 |
To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | % change (Mean) |
|---|---|
| Mid Dose Idebenone | -0.075 |
| High Dose Idebenone | 0.12 |
| Placebo | -3.04 |
1 review available for idebenone and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Idebenone: an emerging therapy for Friedreich ataxia.
Topics: Animals; Antioxidants; Cardiomyopathy, Hypertrophic; Friedreich Ataxia; Humans; Nervous System Disea | 2009 |
3 trials available for idebenone and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA).
Topics: Adolescent; Antioxidants; Cardiomyopathy, Hypertrophic; Child; Clinical Trials, Phase III as Topic; | 2011 |
Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial.
Topics: Adolescent; Adult; Benzoquinones; Cardiomyopathy, Hypertrophic; Child; Erythrocytes; Female; Frataxi | 2003 |
Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring.
Topics: Adolescent; Adult; Benzoquinones; Cardiomyopathy, Hypertrophic; Child; Erythrocytes; Female; Frataxi | 2003 |
2 other studies available for idebenone and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
[Successful idebenone therapy of hypertrophic cardiomyopathy in Friedreich ataxia].
Topics: Adolescent; Antioxidants; Benzoquinones; Cardiomyopathy, Hypertrophic; Child; Echocardiography; Elec | 2003 |
Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia.
Topics: Administration, Oral; Adolescent; Adult; Antioxidants; Benzoquinones; Cardiomyopathy, Hypertrophic; | 2002 |